FDA Grants AP Status for Succinylcholine Chloride ANDA217873
The FDA has granted approval status (AP) for ANDA217873, a generic formulation of Succinylcholine Chloride by STERISCIENCE.
Therapeutic Area
Therapeutic area intelligence for Neuromuscular Blocker with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.